212 related articles for article (PubMed ID: 23548526)
1. Analysis of hereditary angioedema attacks requiring a second dose of ecallantide.
Li HH; Campion M; Craig TJ; Soteres DF; Riedl M; Lumry WR; MacGinnitie AJ; Shea EP; Bernstein JA
Ann Allergy Asthma Immunol; 2013 Mar; 110(3):168-72. PubMed ID: 23548526
[TBL] [Abstract][Full Text] [Related]
2. Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks.
Sheffer AL; MacGinnitie AJ; Campion M; Stolz LE; Pullman WE
Ann Allergy Asthma Immunol; 2013 Mar; 110(3):184-188.e2. PubMed ID: 23548529
[TBL] [Abstract][Full Text] [Related]
3. Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema.
Bernstein JA; Shea EP; Koester J; Iarrobino R; Pullman WE
Allergy; 2012 Sep; 67(9):1173-80. PubMed ID: 22765833
[TBL] [Abstract][Full Text] [Related]
4. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema.
Levy RJ; Lumry WR; McNeil DL; Li HH; Campion M; Horn PT; Pullman WE
Ann Allergy Asthma Immunol; 2010 Jun; 104(6):523-9. PubMed ID: 20568386
[TBL] [Abstract][Full Text] [Related]
5. Use of ecallantide in pediatric hereditary angioedema.
MacGinnitie AJ; Davis-Lorton M; Stolz LE; Tachdjian R
Pediatrics; 2013 Aug; 132(2):e490-7. PubMed ID: 23878046
[TBL] [Abstract][Full Text] [Related]
6. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor.
Schneider L; Lumry W; Vegh A; Williams AH; Schmalbach T
J Allergy Clin Immunol; 2007 Aug; 120(2):416-22. PubMed ID: 17559913
[TBL] [Abstract][Full Text] [Related]
7. Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics.
MacGinnitie AJ; Campion M; Stolz LE; Pullman WE
Allergy Asthma Proc; 2012; 33(2):178-85. PubMed ID: 22525395
[TBL] [Abstract][Full Text] [Related]
8. Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials.
Banta E; Horn P; Craig TJ
Allergy Asthma Proc; 2011; 32(4):319-24. PubMed ID: 21781409
[TBL] [Abstract][Full Text] [Related]
9. Prospective, double-blind, placebo-controlled trials of ecallantide for acute attacks of hereditary angioedema.
Stolz LE; Sheffer AL
Expert Rev Clin Immunol; 2012 Jan; 8(1):25-32. PubMed ID: 22149337
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study.
Lumry WR; Bernstein JA; Li HH; MacGinnitie AJ; Riedl M; Soteres DF; Craig TJ; Campion M; Iarrobino R; Stolz LE; Pullman WE
Allergy Asthma Proc; 2013; 34(2):155-61. PubMed ID: 23484891
[TBL] [Abstract][Full Text] [Related]
11. Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies.
Sheffer AL; Campion M; Levy RJ; Li HH; Horn PT; Pullman WE
J Allergy Clin Immunol; 2011 Jul; 128(1):153-159.e4. PubMed ID: 21481442
[TBL] [Abstract][Full Text] [Related]
12. Current characteristics associated with hereditary angioedema attacks and treatment: the home infusion based patient experience.
Tachdjian R; Banerji A; Guyer A; Morphew T
Allergy Asthma Proc; 2015; 36(2):151-9. PubMed ID: 25715244
[TBL] [Abstract][Full Text] [Related]
13. Ecallantide: in acute hereditary angioedema.
Garnock-Jones KP
Drugs; 2010 Jul; 70(11):1423-31. PubMed ID: 20614949
[TBL] [Abstract][Full Text] [Related]
14. Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency.
Rubinstein E; Stolz LE; Sheffer AL; Stevens C; Bousvaros A
BMC Gastroenterol; 2014 Apr; 14():71. PubMed ID: 24712435
[TBL] [Abstract][Full Text] [Related]
15. Response time for ecallantide treatment of acute hereditary angioedema attacks.
Riedl M; Campion M; Horn PT; Pullman WE
Ann Allergy Asthma Immunol; 2010 Dec; 105(6):430-436.e2. PubMed ID: 21130380
[TBL] [Abstract][Full Text] [Related]
16. Ecallantide for treatment of acute attacks of hereditary angioedema.
Martello JL; Woytowish MR; Chambers H
Am J Health Syst Pharm; 2012 Apr; 69(8):651-7. PubMed ID: 22472866
[TBL] [Abstract][Full Text] [Related]
17. Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks.
Craig TJ; Li HH; Riedl M; Bernstein JA; Lumry WR; MacGinnitie AJ; Stolz LE; Biedenkapp J; Chyung Y
J Allergy Clin Immunol Pract; 2015; 3(2):206-212.e4. PubMed ID: 25609335
[TBL] [Abstract][Full Text] [Related]
18. Icatibant for the treatment of hereditary angioedema.
Cole SW; Lundquist LM
Ann Pharmacother; 2013 Jan; 47(1):49-55. PubMed ID: 23249729
[TBL] [Abstract][Full Text] [Related]
19. Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial.
Lumry WR; Li HH; Levy RJ; Potter PC; Farkas H; Moldovan D; Riedl M; Li H; Craig T; Bloom BJ; Reshef A
Ann Allergy Asthma Immunol; 2011 Dec; 107(6):529-37. PubMed ID: 22123383
[TBL] [Abstract][Full Text] [Related]
20. C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks--final results of the I.M.P.A.C.T.2 study.
Craig TJ; Bewtra AK; Bahna SL; Hurewitz D; Schneider LC; Levy RJ; Moy JN; Offenberger J; Jacobson KW; Yang WH; Eidelman F; Janss G; Packer FR; Rojavin MA; Machnig T; Keinecke HO; Wasserman RL
Allergy; 2011 Dec; 66(12):1604-11. PubMed ID: 21884533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
